Barbara Finck

4.8k citations

17 papers · 3.6k indexed · 3 hit papers · h-index 8

Impact in

Rheumatology top 0.2%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research

Papers in

Immunology 10
- Biosimilars and Bioanalytical Methods 7
- T-cell and B-cell Immunology 3
Hematology 5
- Autoimmune and Inflammatory Disorders Research 4

Co-authors: Daniel Burge Ann VanderStoep James M. Metz Philip J. Mease Bernard S. Goffe Mary Chester Wasko Arthur L. Weaver Joseph A. Markenson
Journals: Advances in Therapy (4 papers)Annals of the Rheumatic Diseases (3 papers)Journal of Clinical Oncology (2 papers)New England Journal of Medicine (1 paper)The Lancet (1 paper)
Partner nations: United States Canada Belarus

In The Last Decade

Barbara Finck

17 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes 2002 · 573 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2002 Arthritis & Rheumatism
2000 The Lancet
2000 New England Journal of Medicine

Peers

Countries citing papers authored by Barbara Finck

Since Specialization

Citations

This map shows the geographic impact of Barbara Finck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Finck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Finck more than expected).

Fields of papers citing papers by Barbara Finck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Finck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Finck. The network helps show where Barbara Finck may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Barbara Finck, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Barbara Finck Line = papers co-authored together Barbara Finck links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work
1	A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants Advances in Therapy ·Hong Tang, Francesca Civoli, Suyama Yasuhiro, Agus Prastya, Barbara Finck	2024	1
2	Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male Participants Advances in Therapy ·Hong Tang, Francesca Civoli, Suyama Yasuhiro, Agus Prastya, Barbara Finck	2023	3
3	A randomized, open-label, crossover study assessing the pharmacokinetic and pharmacodynamic bioequivalence of pegfilgrastim-cbqv via on-body injector vs prefilled syringe. Journal of Clinical Oncology ·Hong Tang, Francesca Civoli, Suyama Yasuhiro, Anjalee Hou, Runqing Diao, Alasdair R. Young, Barbara Finck	2022	1
4	Letter to the Editor Regarding “The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence” Advances in Therapy ·Barbara Finck, Robert B. Geller, Heena S. Naikwadi	2021	2
5	Pharmacokinetic and Pharmacodynamic Equivalence of Pegfilgrastim-cbqv and Pegfilgrastim in Healthy Subjects Advances in Therapy ·Barbara Finck, Helen Tang, Francesca Civoli, Jennifer Hodge, Runqing Diao, Vladimir Vexler	2020	14
6	CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study (S50.002) Neurology ·David Weinstein, R Krzyzanowski, Zhong‐Xu Hu, Hong Tang, R. Przybylo, Robert Zivadinov, Barbara Finck	2017	6
7	Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects. Journal of Clinical Oncology ·John A. Glaspy, Paula G. O’Connor, Hong Tang, Barbara Finck	2017	4
8	OP0220 Randomized, double-blind, global clinical trial to evaluate equivalence of CHS-1420 to adalimumab in patients with psoriasis and psoriatic arthritis Annals of the Rheumatic Diseases ·James R. O’Dell, Alan Kivitz, Kim Papp, C. Leonardi, Kristian H. R. Jensen, Hong Tang, Barbara Finck	2017	3
9	SAT0162 Switching from etanercept to CHS-0214: a one year, randomized, double-blind study in patients with rheumatoid arthritis Annals of the Rheumatic Diseases ·James R. O’Dell, Alan Kivitz, Tsutomu Takeuchi, Yoshiya Tanaka, Ingrid Louw, Elling Rishoff, S. Nakashima, Linda Eaton, Hong Tang, Barbara Finck	2017	3
10	OP0226 Randomized, Double-Blind Study Comparing Chs-0214 with Etanercept in Patients with Active Rheumatoid Arthritis (RA) despite Methotrexate (MTX) Therapy Annals of the Rheumatic Diseases ·James R. O’Dell, Tsutomu Takeuchi, Yoshiya Tanaka, Ingrid Louw, Elling Rishoff, Tiffany Winter, Rui Zhu, S. Nakashima, Barbara Finck	2016	12
11	Long‐term efficacy and safety of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open‐label, extended‐treatment trial Arthritis & Rheumatism ·Daniel J. Lovell, Edward H. Giannini, Andreas Reiff, (unknown), Rayfel Schneider, Judyann C. Olson, Leonard D. Stein, Abraham Gedalia, Norman T. Ilowite, Carol A. Wallace, M. Lange, Barbara Finck, Daniel Burge, (unknown)	2003	182
12	Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes Arthritis & Rheumatism ·Mark C. Genovese, Joan M. Bathon, Richard W. Martin, Roy Fleischmann, John Tesser, Michael Schiff, Edward Keystone, Mary Chester Wasko, Larry W. Moreland, Arthur L. Weaver, Joseph A. Markenson, Grant W. Cannon, G Spencer-Green, Barbara Finck Hit paper breakdown →	2002	573
13	Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial The Lancet ·Philip J. Mease, Bernard S. Goffe, James M. Metz, Ann VanderStoep, Barbara Finck, Daniel Burge Hit paper breakdown →	2000	1111
14	A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis New England Journal of Medicine ·Joan M. Bathon, Richard W. Martin, Roy Fleischmann, John Tesser, Michael Schiff, Edward Keystone, Mark C. Genovese, Mary Chester Wasko, Larry W. Moreland, Arthur L. Weaver, Joseph A. Markenson, Barbara Finck Hit paper breakdown →	2000	1404
15	Enhanced Lymphoproliferation and Diminished Autoimmunity in CD4-deficient MRL/lprMice Clinical Immunology and Immunopathology ·Mark S. Chesnutt, Barbara Finck, Nigel Killeen, M. Kari Connolly, Olena Dobrozorova, David Wofsy	1998	44
16	Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. Journal of Clinical Investigation ·Barbara Finck, Betty S. Chan, David Wofsy	1994	201
17	The role of T-cell subsets in the response to anti-CD3 monoclonal antibodies Clinical Immunology and Immunopathology ·Barbara Finck, Christianne Yung, Nancy Carteron, David Wofsy	1992	6

About Barbara Finck

Barbara Finck is a scholar working on Immunology, Hematology, Rheumatology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 17 papers that have together received 3.6k indexed citations. Recurring topics across this work include Biosimilars and Bioanalytical Methods (7 papers), Neutropenia and Cancer Infections (5 papers), Blood disorders and treatments (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Rheumatoid Arthritis Research and Therapies (4 papers), Autoimmune and Inflammatory Disorders Research (4 papers), T-cell and B-cell Immunology (3 papers) and Health Systems, Economic Evaluations, Quality of Life (2 papers). The work is most often cited by research in Rheumatology (2.7k citations), Hematology (1.5k citations), Immunology (1.3k citations), Genetics (375 citations) and Dermatology (184 citations). Barbara Finck has collaborated with scholars based in United States, Canada and Belarus. Frequent co-authors include Daniel Burge, Ann VanderStoep, James M. Metz, Philip J. Mease, Bernard S. Goffe, Mary Chester Wasko, Arthur L. Weaver, Joseph A. Markenson, Edward Keystone and Richard W. Martin. Their work appears in journals such as Advances in Therapy, Annals of the Rheumatic Diseases, Journal of Clinical Oncology, New England Journal of Medicine and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact